您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (8): 55-59.doi: 10.6040/j.issn.1671-7554.0.2015.1345

• • 上一篇    下一篇

培哚普利对慢性心力衰竭患者血浆miR-423-5p的调控及对心功能的影响

姜蕴珊1,谈红2,李晓燕2,苏莉3,张国明2,张红明2,孟楠1   

  1. 1.锦州医科大学济南军区总医院研究生培养基地, 山东 济南 250031;2.济南军区总医院心内科, 山东 济南 250031;3.济南军区总医院干部二科, 山东 济南 250031
  • 收稿日期:2015-12-28 出版日期:2016-08-10 发布日期:2016-08-10
  • 通讯作者: 谈红. E-mail:tanhong3769@163.com E-mail:tanhong3769@163.com
  • 基金资助:
    贵州省科技攻关项目(SY20103081);济南军区总医院院长基金(2013MS05)

Effects of perindopril on the expression of plasma miR-423-5p and cardiac function in patients with heart failure

JIANG Yunshan1, TAN Hong2, LI Xiaoyan2, SU Li3, ZHANG Guoming2, ZHANG Hongming2, MENG Nan1   

  1. 1. Base of Postgraduate Education, General Hospital of Jinan Military Command, Jinzhou Medical University, Jinan 250031, Shandong, China;
    2. Department of Cardiology, General Hospital of Jinan Military Command, Jinan 250031, Shandong, China;
    3. Second Department of Cadre, General Hospital of Jinan Military Command, Jinan 250031, Shandong, China
  • Received:2015-12-28 Online:2016-08-10 Published:2016-08-10

PDF (PC)

509

摘要： 目的 探讨不同剂量培哚普利对慢性心力衰竭患者血浆miR-423-5p表达的影响及与心功能之间的相关性。 方法 选取慢性心力衰竭患者75例,随机分为常规组(常规药物治疗)、小剂量组(常规药物+4 mg/d培哚普利)和大剂量组(常规药物+8 mg/d培哚普利),每组25例。选取同期健康查体心功能正常人群25例(正常对照组)。经药物治疗4周,检测各组治疗前后左室舒张末内径(LVEDD)、左室射血分数(LVEF)、氨基末端脑利钠肽前体(NT-proBNP)及血浆miR-423-5p的表达水平。 结果 基线水平常规组、小剂量组、大剂量组LVEF的表达均显著低于正常对照组(P<0.05),LVEDD、NT-proBNP及血浆miR-423-5p的表达均显著高于正常对照组(P<0.05);治疗4周后常规组、小剂量组、大剂量组LVEF的表达均较治疗前显著升高(P<0.05),LVEDD、NT-proBNP、血浆miR-423-5p的表达均较治疗前显著降低(P<0.05);治疗后小剂量组和大剂量组LVEF的表达均显著高于常规组(P<0.05),LVEDD、NT-proBNP、血浆miR-423-5p的表达均显著低于常规组(P<0.05);同时,与小剂量组比较,大剂量组LVEF、LVEDD、NT-proBNP、血浆miR-423-5p的表达水平变化呈显著差异(P<0.05)。 结论 培哚普利可以降低慢性心力衰竭患者血浆miR-423-5p的表达水平,进而改善左室功能,其改善程度与药物剂量呈正相关。

关键词: 培哚普利, 左室射血分数, 氨基末端脑利钠肽前体, 心力衰竭, MicroRNA-423-5p

Abstract: Objective To explore the effects of perindopril with different doses on the expression of plasma miR-423-5p in patients with chronic heart failure(CHF)and its correlation with the cardiac function. Methods A total of 75 CHF patients were randomly divided into 3 groups: routine group(n=25, treated with routine medicine), low-dose group(n=25, treated with 4 mg/d perindopril), and high-dose group(n=25, treated with 8 mg/d perindopril). Another 25 healthy controls were enrolled in the control group. After 4 weeks of treatment, pre- and post-treatment levels of LVEDD, LVEF, NT-proBNP, and miR-432-5p of all subjects were measured. Results The baseline level of LVEF of the routine, low-dose and high-dose groups were remarkably lower than that of the control group(P<0.05), while the 山 东 大 学 学 报 (医 学 版)54卷8期 -姜蕴珊,等.培哚普利对慢性心力衰竭患者血浆miR-423-5p的调控及对心功能的影响 \=-baseline levels of LVEDD, NT-proBNP and miR-423-5p of the routine, low-dose and high-dose groups were significantly higher than those of the control group(P<0.05). After 4 weeks of treatment, the level of LVEF of the routine, low-dose and high-dose groups remarkably increased(P<0.05), while the levels of LVEDD, NT-proBNP and miR-423-5p remarkably decreased(P<0.05). After treatment, the LVEF of the low-dose and high-dose groups was significantly higher than that of the routine group(P<0.05), while the LVEDD, NT-proBNP and miR-423-5p levels were significantly lower than those of the routine group(P<0.05). Compared with the low-dose group, the high-dose group had more significant different levels of LVEF, LVEDD, NT-proBNP, and miR-423-5p(P<0.05). Conclusion Perindopril can reduce the plasma miR-423-5p expression in CHF patients, and improve the cardiac function in a dose dependent manner.

Key words: Left ventricular ejection fraction, Heart failure, MicroRNA-423-5p, Perindopril, N-terminal pro-brain natriuretic peptide

中图分类号: 

  • R541.4
[1] Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators[J]. N Engl J Med, 2000, 342(3): 145-153.
[2] Group CM. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators[J]. N Engl J Med, 1991, 325(5): 293-302.
[3] 谈红, 陈瑞敏, 李晓燕, 等. 瑞舒伐他汀对急性冠脉综合征患者CD4+T淋巴细胞miRNA表达的影响[J]. 解放军医学杂志, 2014, 39(2): 99-104. TAN Hong, CHEN Ruimin, LI Xiaoyan, et al. Differences of CD4+T lymphocyte miRNA gene expression in acute coronary artery syndrome(ACS)patients and the effects of rosuvastatin on its expressions[J]. Medical Journal of Chinese Peoples Liberation Army, 2014, 39(2): 99-104.
[4] 李黎, 张丽华, 李凌, 等. 阿托伐他汀对心肌梗死大鼠心室重构和miRNA-21表达的影响[J]. 郑州大学学报(医学版), 2015, 50(4): 488-492. LI Li, ZHANG Lihua, LI Ling, et al. Effect of atorvastatin on ventricular remodeling and expression of miRNA-21 in rats with myocardial infarction[J]. Journal of Zhengzhou University(Medical Sciences), 2015, 50(4): 488-492.
[5] Tijsen AJ, Creemers EE, Moerland PD, et al. MiR423-5p as a circulating biomarker for heart failure[J]. Circ Res, 2010, 106(6): 1035-1039.
[6] Goren Y, Kushnir M, Zafrir B, et al. Serum levels of microRNAs in patients with heart failure[J]. Eur J Heart Fail, 2012, 14(2):147-154.
[7] Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116(2): 281-297.
[8] Gidlof O, van der Brug M, Ohman J, et al. Platelets activated during myocardial infarction release functional miRNA, which can be taken up by endothelial cells and regulate ICAM1 expression[J]. Blood, 2013, 121(19): 3908-3917.
[9] Besser J, Malan D, Wystub K, et al. MiRNA-1/133a clusters regulate adrenergic control of cardiac repolarization[J]. PLoS One, 2014, 9(11): e113449. doi: 10.1371/journal.pone.0113449.
[10] Neilson JR, Zheng GX, Burge CB, et al. Dynamic regulation of miRNA expression in ordered stages of cellular development[J]. Genes Dev, 2007, 21(5): 578-589.
[11] Topkara VK, Mann DL. Role of microRNAs in cardiac remodeling and heart failure[J]. Cardiovasc Drugs Ther, 2011, 25(2): 171-182.
[12] Thum T, Galuppo P, Wolf C, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure[J]. Circulation, 2007, 116(3): 258-267.
[13] Fan KL, Zhang HF, Shen J, et al. Circulating microRNAs levels in Chinese heart failure patients caused by dilated cardiomyopathy[J]. Indian Heart J, 2013, 65(1): 12-16.
[14] Dickinson BA, Semus HM, Montgomery RL, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure[J]. Eur J Heart Fail, 2013, 15(6): 650-659.
[15] 谈红, 李艳敏, 张红明, 等. 慢性充血性心力衰竭患者血浆miR-423-5p和miR-210-3p的表达变化[J]. 临床心血管病杂志, 2014, 30(12): 1081-1085. TAN Hong, LI Yanmin, ZHANG Hongming, et al. The expression changes of plasma miR-423-5p and miR-210-3p in patients with chronic heart failure[J]. Journal of Clinical Cardiology, 2014, 30(12): 1081-1085.
[16] 陈东昌. 慢性心力衰竭患者血清miRNAs及血红素氧合酶-1的变化及意义[D]. 济南:山东大学, 2014.
[17] Song HM, Zhang J, Deng B, et al. Effects of angiotensin converting enzyme inhibitor with different doses on plasma brain natriuretic peptide and norepinephrine in patients with chronic heart failure[J]. Chinese Medical Journal, 2005, 85(25): 1737-1740.
[18] 谈红, 王雪, 李晓燕, 等. 培哚普利对冠心病患者循环血内皮祖细胞及血管内皮功能的影响[J]. 中国循环杂志, 2015, 30(1): 22-25. TAN Hong, WANG Xue, LI Xiaoyan, et al. Effect of different doses of perindopril on endothelial progenitor cells and vascular endothelial function in patients with coronary artery disease[J]. Chinese Circulation Journal, 2015, 30(1): 22-25.
[1] 申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78.
[2] 贾魁,李治国,程翠婷,李志娟,刘瑞卿. 银杏叶片联合曲美他嗪治疗老年慢性心力衰竭的效果及机制[J]. 山东大学学报 (医学版), 2025, 63(6): 19-26.
[3] 李敬,郝盼盼. 急性心力衰竭患者出入院心率变化与预后相关性[J]. 山东大学学报 (医学版), 2025, 63(4): 75-82.
[4] 刘文钊,张远,马湘萍,魏峰涛,卜培莉. 内皮活化和应激指数预测值与心力衰竭患者死亡风险的关联[J]. 山东大学学报 (医学版), 2025, 63(11): 27-35.
[5] 董雪,赵霞,程子捷,韩毅. 左西孟旦和米力农治疗重症心力衰竭合并肾损伤患者711例的药物经济学评价[J]. 山东大学学报 (医学版), 2022, 60(4): 91-98.
[6] 高燕,朱庆颖,栾明亚,刘科卫. 托伐普坦联合达格列净对心衰大鼠心肌纤维化的影响[J]. 山东大学学报 (医学版), 2022, 60(12): 13-18.
[7] 范晓艳,王元耕,陈泽涛. 黄芪桂枝五物汤治疗心衰的网络药理学机制[J]. 山东大学学报 (医学版), 2022, 60(11): 70-81.
[8] 兰洪涛,贾旭,童洲杰,郑曼,胡伯昂,钟明,张薇,王志浩. 无选择性152例成年慢性心力衰竭患者再入院的危险因素[J]. 山东大学学报 (医学版), 2021, 59(4): 63-69.
[9] 张淑莹,武晓峰,郭丽敏,乔温,彭洁琼,李大庆. 两种阿霉素心力衰竭模型及心功能进展的评估[J]. 山东大学学报 (医学版), 2020, 58(12): 1-7.
[10] 米传晓,刘军妮,邹承伟,周南南. 血清可溶性肿瘤因子2抑制剂、半乳糖凝集素-3蛋白水平在慢性心衰分级及预后中的应用[J]. 山东大学学报 (医学版), 2019, 57(1): 62-67.
[11] 谈红,孟楠,晋群,苏莉,张夏晓,陈英剑,郝哲,刘晓红. 不同剂量培哚普利对兔急性心肌梗死后内皮祖细胞及心功能的影响[J]. 山东大学学报（医学版）, 2017, 55(2): 55-60.
[12] 巩璐伟,周丽珍,苏国海. 培哚普利通过调节Akt-FoxO1通路保护糖尿病性心肌病大鼠心功能损伤[J]. 山东大学学报（医学版）, 2017, 55(10): 65-70.
[13] 许天一,吴萍,王爱玲,陈丽萍. 米力农雾化治疗小儿重症肺炎合并心力衰竭的疗效[J]. 山东大学学报（医学版）, 2016, 54(7): 88-90.
[14] 刘霄岩. 米力农治疗难治性心力衰竭80例临床观察[J]. 山东大学学报（医学版）, 2014, 52(S2): 61-61.
[15] 尹黎波, 李慧萍. 曲美他嗪治疗重症疾患并发 慢性心力衰竭患者的临床疗效[J]. 山东大学学报（医学版）, 2014, 52(S2): 99-100.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发